Kure Kazumasa, Hosoya Masaki, Ueyama Takae, Fukaya Midori, Sugimoto Kiichi, Tomiki Yuichi, Ohnaga Takashi, Sakamoto Kazuhiro, Komiyama Hiromitsu
Department of Coloproctological Surgery, Juntendo University School of Medicine, Tokyo 113-8421, Japan.
Central Research Laboratories, Toyama Industrial Technology Center, Toyama 933-0981, Japan.
Oncol Lett. 2020 Mar;19(3):2286-2294. doi: 10.3892/ol.2020.11335. Epub 2020 Jan 23.
The current study clarified the accuracy of a circulating tumor cell (CTC) detection system to diagnose colorectal cancer using blood samples. The system uses the 'polymeric CTC-chip,' (CTC-chip), which is a microfluidic device that is used for CTC isolation. CTCs are considered sensitive diagnostic biomarkers. However, their concentration in the peripheral blood is low and requires highly sensitive and specific capturing techniques. The capture efficiency of the polymeric CTC-chip was first assessed using cell suspensions of the colorectal cancer cell line HCT-116, which was reported as 90.9% in a phosphate-buffered saline suspension and 65.0% in the blood. The CTC-chip was then used to detect CTCs in blood samples obtained from 13 patients with stage II-IV colorectal cancer. On average, the CTCs/ml was lower in patients with stages II and III colorectal cancer (3.3±2.3) than in those with stage IV (7.0±6.2). In patients with stages II-IV, 92% had ≥1 CTC per ml, which was significantly higher than the positive rate (15%) detected using the carbohydrate antigen 19-9 test (CA19-9). Furthermore, CTCs were detected in all patients with stage II and III colorectal cancer, including a number of patients with negative results for the carcinoembryonic antigen (CEA) and CA19-9 tests. With the polymeric CTC-chip detection system, CTCs can be effective cancer markers, particularly for patients with stage II and III colorectal cancer who often exhibit negative conventional serum marker test results. The CTC-chip system may also facilitate the detection of cancer progression based on CTC concentration.
本研究阐明了一种循环肿瘤细胞（CTC）检测系统利用血样诊断结直肠癌的准确性。该系统使用“聚合物CTC芯片”（CTC芯片），这是一种用于CTC分离的微流控装置。CTC被认为是敏感的诊断生物标志物。然而，它们在外周血中的浓度很低，需要高度灵敏和特异的捕获技术。首先使用结直肠癌细胞系HCT-116的细胞悬液评估聚合物CTC芯片的捕获效率，在磷酸盐缓冲盐溶液悬液中的捕获效率据报道为90.9%，在血液中的捕获效率为65.0%。然后，使用CTC芯片检测从13例II-IV期结直肠癌患者获得的血样中的CTC。平均而言，II期和III期结直肠癌患者的每毫升CTC数量（3.3±2.3）低于IV期患者（7.0±6.2）。在II-IV期患者中，92%的患者每毫升有≥1个CTC，这显著高于使用糖类抗原19-9检测（CA19-9）检测到的阳性率（15%）。此外，在所有II期和III期结直肠癌患者中均检测到CTC，包括一些癌胚抗原（CEA）和CA19-9检测结果为阴性的患者。使用聚合物CTC芯片检测系统，CTC可以成为有效的癌症标志物，特别是对于II期和III期结直肠癌患者，他们通常表现出传统血清标志物检测结果为阴性。CTC芯片系统还可能有助于基于CTC浓度检测癌症进展。
